These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Oral contraceptives. Shearman RP Aust Fam Physician; 1984 Sep; 13(9):685-91. PubMed ID: 6508652 [TBL] [Abstract][Full Text] [Related]
43. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 4. Effects on uterine and cervical epithelia. Bastianelli C; Farris M; Bruni V; Brosens I; Benagiano G Expert Rev Clin Pharmacol; 2020 Feb; 13(2):163-182. PubMed ID: 31975619 [No Abstract] [Full Text] [Related]
44. [Potential advantages of triphasic combined oral contraceptives in the light of recent epidemiological and endocrinometabolic data]. Gaspard U; Dubois M Contracept Fertil Sex (Paris); 1982 Sep; 10(9):551-60. PubMed ID: 12311606 [TBL] [Abstract][Full Text] [Related]
45. OC practice guidelines: minimizing side effects. Darney PD Int J Fertil Womens Med; 1997; Suppl 1():158-69. PubMed ID: 9168375 [TBL] [Abstract][Full Text] [Related]
46. Formulation and noncontraceptive uses of the new, low-dose oral contraceptive. Batzer FR J Reprod Med; 1984 Jul; 29(7 Suppl):503-12. PubMed ID: 6237195 [TBL] [Abstract][Full Text] [Related]
50. [Thirty years after the appearance of the first oral contraceptive, clinical and biological analysis of a new estrogen-progestin combination, a three phase pill containing gestodene]. Belaisch J; Hommais-loufrani B Fertil Contracept Sex; 1988 Apr; 16(4 Suppl):1-8. PubMed ID: 12342078 [TBL] [Abstract][Full Text] [Related]
51. The pharmacologic and metabolic effects of oral contraceptives. Mishell DR Int J Fertil; 1989; 34 Suppl():21-6. PubMed ID: 2576252 [TBL] [Abstract][Full Text] [Related]
52. Rationale for new oral contraceptive dosing. Williams JK Int J Fertil Womens Med; 2004; 49(1):30-5. PubMed ID: 15038507 [TBL] [Abstract][Full Text] [Related]
53. [The mechanism of action of oral contraceptives]. Manuilova IA Akush Ginekol (Mosk); 1971 Feb; 47(2):3-8. PubMed ID: 4940751 [No Abstract] [Full Text] [Related]
54. Blockade of mineralocorticoid receptor ameliorates oral contraceptive-induced insulin resistance by suppressing elevated uric acid and glycogen synthase kinase-3 instead of circulating mineralocorticoid. Adeyanju OA; Michael OS; Soladoye AO; Olatunji LA Arch Physiol Biochem; 2020 Jul; 126(3):225-234. PubMed ID: 30318954 [No Abstract] [Full Text] [Related]
55. Effect of Progesterone and Synthetic Progestins on Whole Blood Clot Formation and Erythrocyte Structure. Swanepoel AC; Emmerson O; Pretorius E Microsc Microanal; 2017 Jun; 23(3):607-617. PubMed ID: 28480839 [TBL] [Abstract][Full Text] [Related]
56. Oestrogenic potency and oral contraceptives. Br Med J; 1975 Jun; 2(5972):651-2. PubMed ID: 1169999 [No Abstract] [Full Text] [Related]
58. Progestin isoforms provide different levels of protein S expression in HepG2 cells. Kozuka T; Tamura S; Kawamura N; Nakata Y; Hasebe R; Makiyama A; Takagi Y; Murata M; Mizutani N; Takagi A; Kojima T Thromb Res; 2016 Sep; 145():40-5. PubMed ID: 27447084 [TBL] [Abstract][Full Text] [Related]
59. Ovulation incidence with oral contraceptives: a literature review. Milsom I; Korver T J Fam Plann Reprod Health Care; 2008 Oct; 34(4):237-46. PubMed ID: 18854069 [TBL] [Abstract][Full Text] [Related]
60. [Calcium and bone metabolism across women's life stages. The effects of oral contraceptives/low dose estrogen-progestin on bone metabolism, bone mass and geometry in adolescent and young adult women.]. Okano H Clin Calcium; 2017; 27(5):661-671. PubMed ID: 28439054 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]